Just published: A Nature research paper reports reduced effectiveness of vaccine- or infection-elicited antibodies against the SARS-CoV-2 Omicon variant, relative to other viral lineages
and is provided in this format here as a response to the exceptional public-health crisis. This accepted manuscript will continue through the processes of copy editing and formatting to publication of a finalized version of record on nature.com. Please note there may be errors present in this version, which may affect the content, and all legal disclaimers apply.
The Omicron variant of severe acute respiratory syndrome coronavirus 2 was initially identified in November of 2021 in South Africa and Botswana as well as in a sample from a traveler from South Africa in Hong Kong. Since then, B.1.1.529 has been detected globally. This variant seems to be at least equally infectious than B.1.617.2 , has already caused super spreader eventsand has outcompeted Delta within weeks in several countries and metropolitan areas. B.1.1.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
SARS-CoV-2 infection in free-ranging white-tailed deer - NatureNature - <ArticleTitle Language="En" xml:lang="en">SARS-CoV-2 infection in free-ranging white-tailed deer</ArticleTitle>
Read more »
Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variantA Science analysis of the cryogenic electron microscopy structures of the full-length spike trimers of the Delta, Kappa and Gamma variants of SARSCoV2 has identified properties that might account for the Delta variant's heightened transmissibility.
Read more »
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodiesNature research paper: Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Read more »
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shiftNature research paper: Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Read more »
Allelic variation in class I HLA determines CD8+ T cell repertoire shape and cross-reactive memory responses to SARS-CoV-2Studying ~56 million T cells from 55 COVID patients, researchers in SciImmunology offer a high-res picture of epitope reactivity and TCR usage in CD8 T cells specific for SARSCoV2, some of which also react to “common cold” coronaviruses.
Read more »
A Phase 2a clinical trial of Molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virusNew in ScienceTM: A Phase 2a clinical trial of Molnupiravir in patients with COVID19 shows accelerated SARSCoV2 RNA clearance and elimination of infectious virus.
Read more »